Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
Bruno VergèsLaurence DuvillardJean Paul Pais de BarrosBenjamin BouilletSabine Baillot-RudoniAlexia RoulandJean-Michel PetitPascal DegraceLaurent DemizieuxPublished in: Diabetes care (2021)
Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL1, VLDL2, IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D.